DOI: https://doi.org/10.54393/pjhs.v5i11.2402

PAKISTAN JOURNAL OF HEALTH SCIENCES
(LAHORE)
https://thejas.com.pk/index.php/pjhs
ISSN (P): 2790-9352, (E): 2790-9344
Volume 5, Issue 11 (November 2024)

Systematic Review

OPEN ACCESS

Managing Clinical Trials Amid Healthcare Policy Reforms: Challenges and Opportunities

Babar Hayat[1], Naheed Mumtaz[2], Sadia choudry[3], Muhammad Ayub Khan[4], Amna Iqbal Butt[5], Zahid Azam Chaudry[6] and Muhammad Hassain[7*]

[1]Department of Primary and Secondary Healthcare, Government of Pakistan, Lahore, Pakistan
[2]Faculty of Medical and Health Sciences, University of Poonch, Rawalakot, Pakistan
[3]Department of Behavioral Science, Rahbar Medical and Dental College, Lahore, Pakistan
[4]Chughtai Medical Centre, Lahore, Pakistan
[5]Department of Community Medicine, Sharif Medical and Dental College, Lahore, Pakistan
[6]Department of Community Medicine, Nazwaz Sharif Medical College, Gujrat, Pakistan
[7]Department of Molecular Pathology, University of Health Sciences, Lahore, Pakistan

ARTICLE INFO

Keywords:
Clinical Trials Management, Healthcare Policy Reforms, Patient Recruitment, Challenges

How to Cite:
Hayat, B., Mumtaz, N., Choudry, S., Khan, M. A., Butt, A. I., Chaudry, Z. A., & Hussain, M. (2024). Managing Clinical Trials Amid Healthcare Policy Reforms: Challenges and Opportunities: Managing Clinical Trials and Healthcare Policy Reforms. Pakistan Journal of Health Sciences, 5(11), 304-312. https://doi.org/10.5 4393/pjhs.v5i11.2402

Corresponding Author:
Muhammad Hassain
Department of Molecular Pathology, University of Health Sciences, Lahore, Pakistan
muhammadhussainmh173@gmail.com

Received Date: 2nd October, 2024
Acceptance Date: 23rd November, 2024
Published Date: 30th November, 2024

ABSTRACT

Clinical trial management is becoming more influenced by policies in healthcare reform, especially if those reforms are actively affecting regulations, access to healthcare, and compliance. **Objectives:** To find out the implications of healthcare reforms for the administration, supervision and outcomes of the clinical trials. **Methods:** This study was carried out according to the PRISMA guidelines. Eight scholarly databases of peer-reviewed research articles were used including PubMed, ScienceDirect, and Google Scholar. For this review, articles published from January 2016 to April 2024 were collected. This paper reviewed articles centred on the impact of healthcare reform policies on clinical trials, especially in chronic diseases and novel therapies in North America, Europe, and Asia. Through screening, 96 articles were taken for initial screening. 16 articles were fully reviewed based on challenges and prospects of clinical trial management in the course of changes in healthcare system reforms. **Results:** Healthcare policy reforms face obstacles like regulatory challenges, added bureaucracy, and highly volatile patient care accessibility. But there are also some benefits like optimized approval of trials-based procedures, better patient engagement, and increased trial effectiveness. **Conclusions:** It was concluded that clinical research can be more effective and scalable if proactive adaptive strategies are integrated and trial protocols are aligned with evolving policy changes. Adapting proven trial management practices in healthcare settings has the potential to enhance patient outcomes and promote operational efficiency in clinical research around the world.

INTRODUCTION

Clinical Trials Management (CTM) is key to the development of new medical interventions and is vital to the paradigm of ensuring ethical, efficient, regulatory-compliant trials. It includes the elaboration of clinical trials, their coordination, their realization and their control. It has to be ensured that each stage of the study is realized according to ethical rules and scientific protocols. If we talk about advancement the complexity of CTM has been dramatically augmented by the globalization of clinical trials, the requirement of a diverse patient population, and evolving requirements in recent years. It not only enables the protection of participants but also provides an important assurance of scientific credibility and reliability of the results, which is essential for regulatory approval allowing medical products to be commercialized [1]. This work demonstrates how current healthcare policy reforms affect CTM, specifically in-patient safety, data integrity and trial efficiency. This study analyzes the implications of such reforms to highlight the advantages and challenges of optimizing the management of clinical trials. The

DOI: https://doi.org/10.54393/pjhs.v5i11.2402

importance of CTM cannot be overstated. Good management of clinical trials is essential to finish clinical trials on time and within budget while maintaining high standards for patient safety and data hygiene. New clinical trials often hinge on how well they are 'conducted' by getting participants to follow trial protocols and can often make or break a trial's success. Furthermore, efficient CTM can enhance patient retention rates and enable the timely, high-quality collection of data necessary to derive meaningful conclusions on the safety and efficacy of the treatment being studied [2]. In particular, it is important because the costs of clinical trials are escalating and delays in trials can substantially add to sponsors' financial burdens [3]. However, the implementation of CTM practices varies widely by regulation resource availability, and the type of infrastructure of clinical research within which they are conducted globally. Clinical trials in developed regions like North America or Europe benefit from a strong regulatory framework, advanced technology and well-equipped infrastructures making trials quite a smooth function. On the other hand, challenges to CTM are more numerous in emerging markets such as Asia and Africa due to limited resources, absence of stringent oversight, and lower levels of expertise in different clinical research management [4]. Despite these challenges, there is a growing movement to harmonize CTM practices to make sure that trials are conducted according to the same ethical and scientific standards in different regions [5]. Despite the large literature on CTM, however, there are still gaps. The first is that while there is much research on the technical and logistical side of managing clinical trials, relatively few studies have examined how healthcare reforms affect CTM practice. Due to healthcare policies and regulatory changes focusing on increasing transparency, patient safety and using real-world data in trial designs, the CTM has transformed its landscape [6]. However, the implications of these reforms for the administration, supervision and outcomes of clinical trials have thus far gone unexplored. More research is needed to look at how these reforms impact day to day management of trials and to discover what challenges (and opportunities) they present to trial sponsors and contract research organizations [7]. Because of these gaps, this study is very important for addressing: the implication of healthcare policy reforms on the management, supervision and outcomes of clinical trials. This study attempts to gain insight into the challenges that trial managers experience when they need to adapt to new regulatory requirements as well as what could be improved to enhance trial efficiency and patient outcomes [8-10]. The future of CTM, however, is likely to be determined by additional changes in healthcare policy in terms of regulation. The use of real-world data, decentralized clinical trials (DCTs) and greater patient input into the trial design are some trends likely to revolutionize CTM shortly.

This study aims to extend the literature with a detailed assessment of CTM under healthcare reforms and suggestions for optimizing clinical trial management in future. As the landscape of healthcare systems evolves globally, it will be imperative for CTM practices to change with them so that clinical trials can be conducted in a manner which is efficient and ethical but also satisfies both patients as well as regulatory authorities.

METHODS

This study was carried out according to the PRISMA guidelines. A total of 96 articles were focused on the relationship between CTM and healthcare policy reform. The studies included were published in English between the years 2016 and 2024, contributing to the understanding of the challenges and possibilities of conducting clinical trials in different regions and healthcare systems. Filtering criteria focused on articles that identified how healthcare policy reforms impact clinical trial management (CTM) in North America, Europe, and Asia. Studies that examined CTM-related topics, including regulatory challenges, patient safety, data integrity, and operational efficiency, were eligible. Non-peer-reviewed sources (e.g., editorials, commentaries), studies having hydrodynamical applications only (without CTM implication) or languages other than English, have been disqualified as exclusion criteria. Also, we excluded duplicates as well as studies with unavailable full text. The following manuscripts were systematically evaluated and were incorporated into the PRISMA framework: authorship, year, country, trial design, obstacles faced, possible solutions, results, and important issues. The search was extended to several electronic databases: PubMed, Science Direct, Springer Link and Google Scholar, where 80% of articles were acquired from PubMed. The keywords used were “clinical trials management”, “healthcare reforms”, “legal aspects”, “patient recruitment”, and “chronic disease trial management”. A variety of research designs are included in the study: randomized controlled trials (RCTs), observational cohort studies and cross-sectional studies to ensure that the healthcare policy reforms have their effects on clinical trial management (CTM). Randomized controlled trials can provide rigorous, quantitative insights about adherence to protocols, patient retention, and data quality, key components of CTM effectiveness which are lacking in observational research. Observational cohort studies provide important real-world data, permitting investigation of CTM's longitudinal trends over time, and across different healthcare systems. These findings complemented cross-sectional studies, which illustrate, in almost immediate snapshots, specific recruitment

DOI: https://doi.org/10.54393/pjhs.v5i11.2402

obstacles and regulatory compliance problems provided by policy changes that trial managers face during their studies. To begin with, every article that contained any keywords about clinical trial management and health care reform was accumulated. They involved duplications and abstracts. The next phase consisted of screening these articles in terms of certain defined inclusion and exclusion criteria. Similarly, other articles were discarded because the contexts of CTM in the field of health care reform were not relevant, it was not a clinical study, or it was published outside the time range specified. After this screening, 96 articles were considered for detailed analysis but after eliminating duplicates and exclusion of other factors 47 articles were deemed worthy of systematic review. For the last stage of the review, after a full assessment, 16 articles were defended in detail and the core results of studies were arranged into tables by the aspects of challenges and opportunities regarding clinical trial management under health care reforms. The final dataset allowed for a comprehensive understanding of the effects of health systems reform on CTM, considering important aspects like regulatory issues, patient recruitment difficulties, and possible advantages such as better trial quality and participation of patients (Figure 1).



Figure 1: Systematic Review on CMT in Context of Healthcare Policy Reforms According to Inclusion and Exclusion Criteria

RESULTS

The review was performed as per PRISMA guidelines and included 16 most relevant studies, 80 percent of which were from PubMed and the rest from ScienceDirect and Springer Link. Seven of the 16 studies were observational cohort studies, five were randomized controlled trials, and four were cross-sectional studies. These studies aimed to explore the effect of healthcare reforms on trial management, patient recruitment, and data capture as well as management. The evidence showed that although there have been more complexities in the regulations due to healthcare reforms, patient safety and transparency of trials were also enhanced. The use of real-world evidence (RWE) and DCT were especially successful in addressing some of the logistical and recruitment challenges. Quantitative and qualitative findings on the impact of healthcare reforms on clinical trial management (CTM) across several main points are presented. Studies showed a 15% improvement in patient retention for DCTs and a 20% reduction in the academic trials in Japan that helped with the high costs problem. Qualitative insights identify challenges and strategies, including stricter conflict of interest management and the need for better patient-centred designs for improved recruitment and retention. Together, these quantitative and qualitative results underscore the dual impact of healthcare reforms: new regulations can place operational burdens and introduce regional variability, but reforms also offer the potential to develop more efficient, patient-centred and adaptable trial designs, both for regulatory compliance and for patient outcome. The summary of the 16 studies is analyzed (Table 1).

Table 1: Systematic Scheme of Studies Included in Review Along with Their Findings and Outcomes

References	Type of Study	Focus of Study	Challenges Highlighted	Opportunities Identified	Outcomes/Findings
[11]	Observational, longitudinal cohort study	Management of a real-world longitudinal non-alcoholic fatty liver disease (NAFLD) cohort across multiple countries	Variability in data collection across sites; coordinating international multi-center recruitment and maintaining high-quality data	Variability in data collection across sites; coordinating international multi-center recruitment and maintaining high-quality data	Successfully established a large, high-quality database supporting biomarker development and longitudinal analysis for regulatory qualification.

DOI: https://doi.org/10.54393/pjhs.v5i11.2402

[12]	Cross-sectional (clinical trials)	Representation in precision oncology clinical trials	Low representation of racial and ethnic minorities; incomplete reporting of participant demographics across studies	Increasing diversity in participant recruitment through community engagement, patient education, and enhanced reporting practices	Demonstrated the need for better recruitment strategies to ensure equitable representation of minorities in clinical trials.
[13]	Randomized Control Trial	Asia-inclusive development of Pevonedistat for higher-risk MDS, CMML, and AML.	Delays in drugdevelopment in Asia, complexities in harmonizing regional regulatory requirements.	Efficiency in global clinical trials through multiregional clinical trials (MRCT) designs that include regional patients early, thereby reducing delays in drug availability.	Comparable pharma-cokinetics, efficacy, and safety across East Asian and Western populations, enabling pooled analysis for East Asian patients.
[14]	Randomized Controlled Trial (RCT)	General practitioner-led vs. surgeon-led colon cancer survivorship care.	Difficulty recruiting participants, reluctance of GPs to participate, preference for specialized care among patients.	Engagement of new centers and modified recruitment procedures to enhance trial participation.	GP-led survivorship care shows potential but requires more support and participation from both patients and healthcare providers.
[15]	Observational Comparative Effectiveness Study	Cardiovascular and renal benefits of empagliflozin in Type 2 Diabetes routine care settings in East Asia.	Adjusting for regional variations in patient care, healthcare databases, and balancing comorbidities among patient populations.	Routine care data shows consistency with clinical trial findings, emphasizing the drug's broad applicability across various patient profiles.	Empagliflozin reduced heart failure hospitalizations by 18%, all-cause mortality by 36%, and end-stage renal disease by 63% compared to DPP-4 inhibitors.
[16]	Cross-Sectional Study	Factors influencing participation in COVID-19 clinical trials in Arab countries	Lack of trust in physicians, limited information, fear of negative health impacts	Increase awareness, enforce ethical guidelines, and promote altruism	The public has a generally positive attitude towards trials but is influenced by trust issues
[17]	Post Clinical Trial	Regulatory changes in clinical trial management post-enforcement of the Clinical Trials Act	Financial and administrative burdens on academic clinical trials	Improved reliability and stricter conflict-of-interest management under new guidelines	Significant reduction in clinical trial activity post-regulation due to increased burden
[18]	Retrospective Study	Oncology clinical trial management during COVID-19 at Beijing Cancer Hospital.	COVID-19 restrictions led to difficulties in patient recruitment, protocol compliance, and site monitoring.	Remote clinical trial management (remote approvals, visits, drug administration, and monitoring) helped maintain high protocol compliance and trial continuity during pandemic outbreaks.	Remote trial management ensured an 85.24% protocol compliance rate with fewer trial withdrawals and loss to follow-up, compared to traditional management during public health emergencies.
[19]	Observational Study	Site identification practices and the use of electronic health records (EHRs) in feasibility evaluations of clinical trials in the Nordic countries.	Limited use of EHR data for trial site identification due to legislative restrictions and limited investigator engagement with patient data.	Increased use of EHR data for estimating patient recruitment potential could accelerate recruitment and improve the accuracy of feasibility evaluations, leading to better site selection and trial success.	Sites using EHR data were perceived as more reliable and effective in estimating patient recruitment potential, offering a competitive advantage in trial site selection.
[20]	Observational Study Survey	Examines new UK regulatory frameworks for oncology drug approvals after Brexit	Ensuring timely regulatory approvals, maintaining access to drugs, and addressing reimbursement issues	Expedited approval pathways, global collaboration (Project Orbis), and innovative licensing pathways	Faster cancer drug approval times in the UK compared to the EU; earlier patient access through Project Orbis.
[21]	Observational Study	Assesses the implementation of research biopsies in oncology trials at a tertiary center	Ethical concerns regarding the increase in biopsy demands without direct patient benefit; low compliance to ethical frameworks	Improving adherence to ethical frameworks to ensure better quality of care in clinical trials	Increased use of tissue biopsies in clinical trials without significant benefit, highlighting the need for better frameworks.
[22]	Prospective Study	Incorporation of participant feedback before, during, and after trials	Lack of patient-centred trial designs, low recruitment and retention rates due to poor trial design	Use of technology (surveys, apps) to gather feedback, patient-reported outcomes, voice-response technology	Incorporating participant feedback reduces participant burden, improves recruitment and retention, and enhances trial success

DOI: https://doi.org/10.54393/pjhs.v5i11.2402

[23]	Randomized Clinical Trials	On-site monitoring of clinical trials by Ethics Committees in India	Inadequate off-site monitoring, GCP (good clinical practice) violations, protocol violations, discrepancies in informed consent	On-site monitoring ensures better compliance with GCP, protects participant rights, reveals unreported issues	On-site monitoring detected GCP violations missed by off-site reviews, such as incomplete consent forms, unreported adverse events, and protocol violations.

These studies from Japan, India, and globally all show that healthcare reforms, including improved monitoring and regulatory changes, improve clinical trial supervision and participant safety. Reforms also foster inclusivity and patient-centred designs that increase trial recruitment, retention, and overall trial outcomes.

DISCUSSION

Clinical Trials management is an indispensable component of clinical research and plays a crucial role in advancing the field of medical research and the discovery of new therapies. It involves the coordination of the clinical trials to gain assurance that they are running correctly and in compliance with stimulating legal benchmarks and moral principles. Appropriate CTM is crucial to patient safety and to ensure the scientific credibility of the results of the trial. The challenges in CTM have increased over time due to the growing scale of trials across diverse geographic regions, the increasing use of a diverse patient population, and the introduction of new rules and regulations [24]. The focus of this study is to highlight the reforms to healthcare policies and how they have influenced the management, oversight, and outcomes of the clinical trials, aiming to provide details on the challenges and possibilities of these reforms. Some of the most revolutionary changes in clinical trial management have been driven by healthcare policy reforms particularly those concerning patient safety and data integrity. The globalization of clinical trials has also witnessed the implementation of international regulations such as the Clinical Trials Regulation which emphasizes increased transparency, improvements in patient involvement, and usage of real-world data involved in trial design [25]. A variety of factors have significant effects on Clinical trial management, including regulatory frameworks, ethical oversight, patient recruitment, data management, and monitoring processes. The main challenge is the alignment on international regulatory requirements, particularly in multi-regional trials. One study points out problems in harmonizing regulatory requirements for the development of immunotherapy for solid tumors across Europe and Asia [26]. The findings of one study, emphasize the need for on-site monitoring in African trials wherein several protocol violations were not detected by the off-site reviews [27]. However, there is a need for more enhanced monitoring, and this brings the problem of resource allocation and the financial burden of ethics committees and trial sponsors. Yet, the development of risk-based monitoring strategies as well as the use of DCTs can support opportunities by allowing the processes to be streamlined and administrative overheads to be reduced [28]. Clinical trials today are an increasingly complex management affair, especially when trials span multiple regions and need convergence of their regulations. This is observed in the study by analyzing Brazil's updated regulatory framework for clinical trials in rare diseases [29], where the regulatory landscape in Europe, Asia and the Americas varies widely, making trial management complicated. This framework has helped to speed up approval but has also imposed new compliance requirements for local trials. Conversely, in the United States, the reforms brought by the FDA's 2020 patient-focused drug development guidance have helped lead to more inclusive trials for instance even in rare and genetic disorders with involvement of the patient advocacy groups [30]. This is further illustrated by a study on the provision of global collaborations, such as the ACCESS Consortium, that catalyze faster regulatory approvals and more innovative licensing pathways (regulatory harmonization) in pediatric oncology drug approvals [31]. The effective management of clinical trials is essential for the continuous development of safe and effective medical interventions. With healthcare reforms increasingly focusing on patient safety and trial transparency, CTM practices are undergoing significant transformation. Ensuring patient safety through rigorous supervision and monitoring processes is now a cornerstone of clinical trial management. Some studies demonstrate that decentralized trials, driven by technology and patient-centric designs, can improve recruitment and retention in remote or underserved populations, while also reducing trial costs [32]. This emphasis on patient engagement underscores the importance of CTM in ensuring trials are ethical, scientifically sound, and aligned with patient needs. The findings from the studies summarized in the table provide critical insights into how healthcare reforms have shaped clinical trial management. For example, in 2020 Shafiq *et al.*, highlighted the shortcomings in off-site monitoring in India, with on-site monitoring revealing several previously undetected violations, emphasizing the need for reforms in monitoring practices [23]. In Japan, the study by Nakamura and Shibata revealed that the new Clinical Trials Act, while improving trial reliability, imposed significant burdens on academic trials, leading to a reduction in clinical trial activity [17]. Other studies, such as

DOI: https://doi.org/10.54393/pjhs.v5i11.2402

by Zhou *et al.*, showed that multiregional trials while challenging due to regulatory harmonization issues, offer significant opportunities to accelerate drug availability in underserved regions [13]. These results underscore the dual challenges and opportunities that healthcare reforms present for the administration and supervision of clinical trials. Over the last few decades, the management of clinical trials has changed significantly due to various reforms in healthcare institutions especially those affecting patient safety and trials. Some of the major shifts that have occurred include the use of DCTs and the integration of real-world data (RWD) into trial designs [33]. The COVID-19 pandemic has highlighted the importance of DCTs that do not require physical on-site presence [18, 34]. Also, the technology using EDCs and the expansion of EHR (Electronic Health Records) systems have shifted the management of trials and patient recruitment more effectively and efficiently [19, 35]. However, there still exist challenges when it comes to the management of clinical trials especially in light of healthcare reforms. Despite the culture, rules and regulations being important for the protection of the patients and the accuracy of data collected, are known to cause major administrative barriers to the sponsors and investigators of the trials. These burdens, as reported in one study might result in a decline in trial activity especially in academic institutions [36]. Furthermore, the comparative nature of regulations across the regions makes the conduct of multi-regional trials challenging, as mentioned in a study [37]. The inclusion of limited numbers of registers drawn from diverse minorities in clinical research trials revealed the lacking state of precision oncology trials in the United States [38]. These limitations advocate for continued reforms and innovations necessary in CTM to develop the means of addressing these challenges. Consequently, this research is needed to offer a comprehensive review of how healthcare reforms affect clinical trial management (CTM), oversight, and statistics. It offers a unique view of the difficulties and opportunities brought about by healthcare reform for trial sponsors, regulatory agencies, and healthcare policies. The literature and studies reviewed emphasize the need to evolve CTM policies to the changing law and practice in multicenter trials to ensure they remain safer, more cost-effective and accessible to all patients. This paper also puts forward the demand for additional reforms that will help to solve some of the currently existing challenges of clinical trials, in particular through the lens of CTM, with an emphasis on international and adaptive risk-based monitoring (ARM) trials. Based on this it can be expected that further healthcare system reforms which focus on patient safety, trial effectiveness, and diversification will continue to have an impact on the future of CTM. Real-life trials and Integrated Considerations of Real-World Evidence (RWE) are also thought to have great potential in the future of clinical trials as decentralized and less burdensome to patients. Expectedly, regulatory bodies such as Food and Drug Administration (FDA), should advocate for a more diverse trial population even with the guidance given on patient diversity recently. Furthermore, the adoption of new digital health technologies such as wearable and telemonitoring tools will facilitate data collection and improvement in patient engagement and result in better trial outcomes. Despite this, these advancements will require efficient and transparent regulations on a global scale such as regulations are foundational prerequisites to leverage these advancements to execute these innovations and grow infrastructure. Ongoing changes in healthcare reforms including cutting expenses, increasing patient satisfaction and ensuring quality in healthcare products will in turn require CTM practices to adapt to these changes in such a way that they can manage, monitor and achieve success in clinical trials.

CONCLUSIONS

It was concluded that clinical trial management has been greatly impacted by healthcare reforms, which have both challenged and facilitated increased administrative burdens, patient safety and trial transparency. By elucidating the promise of decentralized clinical trials, real-world evidence and patient-centred designs, the study aimed to overcome key issues such as recruitment difficulties and adherence to protocol. The findings underscore the importance of adopting adaptive management strategies and regulatory harmonization to foster what we hope will be efficient and ethical trial practices. With the evolution of healthcare systems, the link between CTM protocols and these reforms will be crucial to achieving sustainable improvement in trial outcomes, patient engagement and research efficiency.

Authors Contribution

Conceptualization: BH, NM, SC
Methodology: BH, NM, SC, MAK, AIB, ZAC, MH
Formal analysis: BH, NM, SC
Writing review and editing: MAK, AIB

All authors have read and agreed to the published version of the manuscript

Conflicts of Interest

All the authors declare no conflict of interest.

Source of Funding

The author received no financial support for the research, authorship and/or publication of this article.

DOI: https://doi.org/10.54393/pjhs.v5i11.2402

REFERENCES

[1] Hashem H, Abufaraj M, Tbakhi A, Sultan I. Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic, (598038). Frontiers in Medicine. 2020 Dec; 7: 1-11. doi: 10.3389/fmed.2020.598038.

[2] Thompson HS, Manning M, Mitchell J, Kim S, Harper FW, Cresswell S *et al.* Factors Associated with Racial/Ethnic Group-Based Medical Mistrust and Perspectives On COVID-19 Vaccine Trial Participation and Vaccine Uptake in the US. Journal of American Medical Association Network Open. 2021 May; 4(5): e2111629. doi: 10.1001/jamanetworkopen.2021.11629.

[3] Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B *et al.* Evolution of the Randomized Clinical Trial in the Era Of Precision Oncology. Journal of American Medical Association Oncology. 2021 May; 7(5): 728-34. doi: 10.1001/jamaoncol.2021.0379.

[4] Forman R, Atun R, McKee M, Mossialos E. 12 Lessons Learned from the Management of the Coronavirus Pandemic. Health Policy. 2020 Jun; 124(6): 577-80. doi: 10.1016/j.healthpol.2020.05.008.

[5] Manoharan K, Jinson J, Ramesh K, George M. Clinical Trial Trends Over the Last 5 Years among the BRICS (Brazil, Russia, India, China, and South Africa) Nations. Perspectives in Clinical Research. 2024 Jul; 15(3): 128-33. doi: 10.4103/picr.picr_179_23.

[6] Chaudhari N, Ravi R, Gogtay NJ, Thatte UM. Recruitment and Retention of the Participants in Clinical Trials: Challenges and Solutions. Perspectives in Clinical Research. 2020 Apr; 11(2): 64-9. doi: 10.4103/picr.PICR_206_19.

[7] Yip W, Powell-Jackson T, Chen W, Hu M, Fe E, Hu M *et al.* Capitation Combined with Pay-For-Performance Improves Antibiotic Prescribing Practices in Rural China. Health Affairs. 2014 Mar; 33(3): 502-10. doi: 10.1377/hlthaff.2013.0702.

[8] Rosenberg M, Sheehan S, Zhou E, Pinnow E, Burnell J, Romine M et al. FDA Postmarketing Safety Labeling Changes: What Have We Learned Since 2010 About Impacts On Prescribing Rates, Drug Utilization, And Treatment Outcomes. Pharmaco-epidemiology and Drug Safety. 2020 Sep; 29(9): 1022-9. doi: 10.1002/pds.5073.

[9] Woodcock J and LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, Or Both. New England Journal of Medicine. 2017 Jul; 377(1): 62-70. doi: 10.1056/NEJMra1510062.

[10] Inan OT, Tenaerts P, Prindiville SA, Reynolds HR, Dizon DS, Cooper-Arnold K *et al.* Digitizing Clinical Trials. Nature Partner Journals Series Digital Medicine. 2020 Jul; 3(1): 101. doi: 10.1038/s41746-020-0302-y.

[11] Hardy T, Wonders K, Younes R, Aithal GP, Aller R, Allison M *et al.* The European NAFLD Registry: A Real-World Longitudinal Cohort Study of Nonalcoholic Fatty Liver Disease. Contemporary Clinical Trials. 2020 Nov; 98: 106175. doi: 10.1016/j.cct.2020.106175.

[12] Aldrighetti CM, Niemierko A, Van Allen E, Willers H, Kamran SC. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. Journal of American Medical Association Network Open. 2021 Nov; 4(11): e2133205-. doi: 10.1001/jamanetworkopen.2021.33205.

[13] Zhou X, Friedlander S, Kupperman E, Sedarati F, Kuroda S, Hua Z *et al.* Asia-Inclusive Global Development of Pevonedistat: Clinical Pharmacology and Translational Research Enabling a Phase 3 Multiregional Clinical Trial. Clinical and Translational Science. 2021 May; 14(3): 1069-81. doi: 10.1111/cts.12972.

[14] Duineveld LA, Vos JA, Wieldraaijer T, Donkervoort SC, Wind J, van Weert HC *et al.* Recruitment Challenges to the I CARE Study: A Randomized Trial On General Practitioner-Led Colon Cancer Survivorship Care. BioMedical Journal Open. 2021 Aug; 11(8): e048985. doi: 10.1136/bmjopen-2021-048985.

[15] Seino Y, Kim DJ, Yabe D, Tan EC, Chung WJ, Ha KH *et al.* Cardiovascular and Renal Effectiveness of Empagliflozin in Routine Care in East Asia: Results from the EMPRISE East Asia Study. Endocrinology, Diabetes and Metabolism. 2021 Jan; 4(1): e00183. doi: 10.1002/edm2.183.

[16] Abdelhafiz AS, Abd ElHafeez S, Khalil MA, Shahrouri M, Alosaimi B *et al.* Factors Influencing Participation in COVID-19 Clinical Trials: A Multi-National Study. Frontiers in Medicine. 2021 Feb; 8: 608959. doi: 10.3389/fmed.2021.608959.

[17] Nakamura K and Shibata T. Regulatory Changes After the Enforcement of the New Clinical Trials Act in Japan. Japanese Journal of Clinical Oncology. 2020 Apr; 50(4): 399-404. doi: 10.1093/jjco/hyaa028.

[18] Fu Z, Jiang M, Wang K, Li J. Minimizing the Impact of the Covid-19 Epidemic on Oncology Clinical Trials: Retrospective Study of Beijing Cancer Hospital. Journal of Medical Internet Research. 2021 Mar; 23(3): e26799. doi: 10.2196/26799.

[19] Laaksonen N, Bengtström M, Axelin A, Blomster J, Scheinin M, Huupponen R. Clinical Trial Site Identification Practices and the Use of Electronic Health Records in Feasibility Evaluations: An Interview Study in the Nordic Countries. Clinical

DOI: https://doi.org/10.54393/pjhs.v5i11.2402

Trials. 2021 Dec; 18(6): 724-31. doi: 10.1177/17407745211038512.

[20] Lythgoe MP, Krell J, Bower M, Murphy R, Marriott J, Blagden SP *et al.* From the European Medicines Agency to Project Orbis: New Activities and Challenges to Facilitate UK Oncology Drug Approval Following Brexit. The Lancet Oncology. 2023 Apr; 24(4): e150-60. doi: 10.1016/S1470-2045(22)00701-X.

[21] Olympios N, Collet L, Paesmans M, Jungels C, Kotecki N, Awada A *et al.* Analyses of the Rationale and Implementation of Research Biopsies in Oncology Clinical Trials at a Tertiary Cancer Center. The oncologist. 2021 Dec; 26(12): 1062-70. doi: 10.1002/onco.13906.

[22] Cruz Rivera S, McMullan C, Jones L, Kyte D, Slade A, Calvert M. The Impact of Patient-Reported Outcome Data from Clinical Trials: Perspectives from International Stakeholders. Journal of Patient-Reported Outcomes. 2020 Dec; 4: 1-4. doi: 10.1186/s41687-020-00219-4.

[23] Shafiq N, Kumari S, Kumar V, Suri V, Jayashree M, Duseja A *et al.* On-site Monitoring of Clinical Trials by an Ethics Committee in India: A Road Less Travelled. Research Ethics. 2021 Jan; 17(1): 45-54. doi: 10.1177/1747016120933923.

[24] Yaakov RA, Güler Ö, Mayhugh T, Serena TE. Enhancing Patient Centricity and Advancing Innovation in Clinical Research with Virtual Randomized Clinical Trials (RCTs). Diagnostics. 2021 Jan; 11(2): 151. doi: 10.3390/diagnostics11020151.

[25] DeVito NJ, Bacon S, Goldacre B. Compliance with Legal Requirement to Report Clinical Trial Results On Clinical trials. Gov: A Cohort Study. The Lancet. 2020 Feb; 395(10221): 361-9. doi: 10.1016/S0140-6736(19)33220-9.

[26] Fogli LK, Aurigemma R, Sommers CL, Singh A, Bourcier K, Ernstoff MS. NCI Cell Therapy Workshop Committee. Challenges and Next Steps in the Advancement of Immunotherapy: Summary of the 2018 and 2020 National Cancer Institute Workshops On Cell-Based Immunotherapy for Solid Tumors. Journal for Immunotherapy of Cancer. 2021; 9(7). doi: 10.1136/jitc-2021-003048.

[27] Wyman Engen N, Huppler Hullsiek K, Belloso WH, Finley E, Hudson F, Denning E *et al.* A Randomized Evaluation of On-Site Monitoring Nested in a Multinational Randomized Trial. Clinical Trials. 2020 Feb; 17(1): 3-14. doi: 10.1177/1740774519881616.

[28] Robinson R, Sacks L. Decentralized Clinical Trials in the Development of Drugs and Biological Products. Therapeutic Innovation and Regulatory Science. 2024 Feb: 1-3. doi: 10.1007/s43441-023-00612-3.

[29] Cunico C, Vicente G, Leite SN. Initiatives to Promote Access to Medicines After Publication of the Brazilian Policy on the Comprehensive Care of People with Rare Diseases. Orphanet Journal of Rare Diseases. 2023 Aug; 18(1): 259. doi: 10.1186/s13023-023-02881-5.

[30] Michos ED, Reddy TK, Gulati M, Brewer LC, Bond RM, Velarde GP *et al.* Improving the Enrollment of Women and Racially/Ethnically Diverse Populations in Cardiovascular Clinical Trials: An Practice Statement. American Journal of Preventive Cardiology. 2021 Dec; 8: 100250. doi: 10.1016/j.ajpc.2021.100250.

[31] Epps C, Bax R, Croker A, Green D, Gropman A, Klein AV *et al.* Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases. Therapeutic Innovation and Regulatory Science. 2022 Nov; 56(6): 964-75. doi: 10.1007/s43441-022-00409-w.

[32] Rajasimha H. The Advent of Patient-Centric Technologies to Combat the High Dropout Rates: Revolutionizing Clinical Trials: Combating Attrition in Clinical Trials: Embracing a Patient-Centric Approach Through Innovative Technologies. Telehealth and Medicine Today. 2024 Apr; 9(2). doi: 10.30953/thmt.v9.474.

[33] Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP, McIntosh E, Petticrew M. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. British Medical Journal. 2021 Sep; 374. doi: 10.1136/bmj.n2061.

[34] De Jong AJ, Van Rijssel TI, Zuidgeest MG, Van Thiel GJ, Askin S, Fons-Martínez J *et al.* Opportunities and challenges for decentralized clinical trials: European regulators' perspective. Clinical Pharmacology and Therapeutics. 2022 Aug; 112(2): 344-52. doi: 10.1002/cpt.2628.

[35] O'Brien EC, Raman SR, Ellis A, Hammill BG, Berdan LG, Rorick T *et al.* The Use of Electronic Health Records for Recruitment in Clinical Trials: A Mixed Methods Analysis of the Harmony Outcomes Electronic Health Record Ancillary Study. Trials. 2021 Dec; 22: 1-8. doi: 10.1186/s13063-021-05397-0.

[36] Hiramatsu K, Barrett A, Miyata Y. PhRMA Japan Medical Affairs Committee Working Group 1. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan. Drugs Real World Outcomes. 2021 Dec; 8(4): 459-80. doi: 10.1007/s40801-021-00266-3.

[37] Bjerregaard V and Singh R. New Principles in Global Development Using ICH E 17 Guideline. In

DOI: https://doi.org/10.54393/pjhs.v5i11.2402

Simultaneous Global New Drug Development. 2021 Dec; 11-30. doi: 10.1201/9781003109785-2.

[38] Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E *et al.* Delivering Precision Oncology to Patients with Cancer. Nature Medicine. 2022 Apr; 28(4): 658-65. doi: 10.1038/s41591-022-01717-2.